Company
About us
History
Leaderships
Team
EU grants
Requests for Proposal
Sustainability – ESG
Bussines strategy
Quality policy
Virtual Tour
Investors
Corporate documents
Shareholders and shares
Periodic reports
Current reports
Sustainability reports
Corporate governance at Mabion
Financial data
For Investors
Calendar
Resources
Science Hub
Press releases
News
Events
Media kit
Services
Process Development
Analytics
Drug Substance Manufacturing
Contact
Contact form
Contact for investors
Contact for media
Careers
Science News
Resources
Biologics
From Research to Release: Mapping Mabion’s Full Analytical Lifecycle for Monoclonal Antibodies
Analytics
,
Mabion
,
Monoclonal antibody
Time to Market Strategy – 5 CDMO Tactics to Speed Up Biologic Launches
Biologics
,
Drug development
,
Manufacturing
Antibodies Development Best Practices for CDMO Collaboration
Drug development
,
Manufacturing
,
Monoclonal antibody
UV-VIS Spectrometry for Protein Concentration Analysis: Principles and Applications
Analytics
,
Biologics
,
Proteins
Innovative Biologics – Expected Drug Approvals in 2025
Antibody-drug conjugates
,
Biologics
,
Bispecific antibody
,
Clinical trials
,
EMA
,
FDA
,
Monoclonal antibody
,
Vaccines
Biologics CDMO Solutions for the Future of Therapeutics
Biologics
,
Drug development
,
Manufacturing
Bioanalytical Assay Strategies and Considerations for Validation of B Cells-Depletion Assay by Flow Cytometry
Bioanalytics
,
Biologics
Top 5 most expected biologics in 2024
Biologics
,
Drug development
,
EMA
,
FDA
,
Regulatory
Similar but not the same: an in-depth look at the differences between EMA and FDA
Biologics
,
EMA
,
FDA
,
Regulatory
Previous
1
2
3
4
Next
